The emergence of multidrug-resistant strains ofMycobacterium tuberculosis has resulted in increased interest in the fluoroquinolones (FQs) as antituberculosis agents. To investigate the frequency and mechanisms of FQ resistance in M. tuberculosis, we cloned and sequenced the wild-type gyrA and gyrB genes, which encode the A and B subunits of the DNA gyrase, respectively; DNA gyrase is the main target of the FQs. On the basis of the sequence information, we performed DNA amplification for sequencing and single-strand conformation polymorphism analysis to examine the presumed quinolone resistance regions ofgyrA and gyrB from reference strains (n = 4) and clinical isolates (n = 55). Mutations in codons ofgyrA analogous to those described in other FQ-resistant bacteria were identified in all isolates (n = 14) for which the ciprofloxacin MIC was >2 ,ug/ml. In addition, we selected ciprofloxacin-resistant mutants of Mycobacterium bovis BCG and M. tuberculosis Erdman and H37ra. Spontaneously resistant mutants developed at a frequency of 1 in 107 to 108 at ciprofloxacin concentrations of 2 ,ug/ml, but no primary resistant colonies were selected at higher ciprofloxacin concentrations. Replating of those first-step mutants selected for mutants with high levels of resistance which harbored gyrA mutations similar to those found among clinical FQ-resistant isolates. The gyrA and gyrB sequence information will facilitate analysis of the mechanisms of resistance to drugs which target the gyrase and the implementation of rapid strategies for the estimation of FQ susceptibility in clinical M. tuberculosis isolates.
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The resurgence of tuberculosis and its incidence in human immunodeficiency virus-positive populations in both developing countries and the industrialized world have been accompanied by the alarming emergence of virulent multidrugresistant tuberculosis (MDR-TB) strains in North American cities (7) . Many of these strains have acquired resistance to almost all first-and second-line antituberculosis agents. For this reason, there is an increasing interest in the antimycobacterial actions of the fluoroquinolones (FQs). Against Mycobacterium tuberculosis, the FQs show moderate in vitro activity (4), with sparfloxacin (MIC, 0.25 to 0.5 ,ug/ml) perhaps being the most effective compound (17) . The principal target of the quinolones is the DNA gyrase, a type II DNA topoisomerase that is composed of two A and two B subunits (30) encoded by gyrA and gyrB, respectively. Mutations in the putative FQbinding region of the A subunit have been found to confer high-level FQ resistance in several bacterial species (8, 19, 22, 31, 33) . Other mutations that confer resistance to quinolones have been found in gyrB, in genes that lower the intracellular concentration of the drug (although these tend to confer lower-level resistance than do the gyrA mutations [32, 34] ), or mapped to loci involved in uncharacterized novel mechanisms of resistance to these agents (27) .
The effectiveness of the FQs in the treatment of tuberculosis may depend on the frequency and mechanisms by which M. tuberculosis develops resistance and the ability to determine rapidly whether the strain from a particular patient remains susceptible to FQs. Rapid susceptibility determination is especially important for the slow-growing M. tuberculosis, because by conventional methods it can take up to 6 to 12 weeks to determine whether the infecting strain is susceptible, a period equal to the median survival time for human immunodeficiency virus-positive patients diagnosed as having MDR-TB infections (7) .
In this report we describe the cloning and sequencing of the M. tuberculosis genes gyrA and gyrB. On the basis of those sequences, we studied clinical M. tuberculosis isolates to find mutations in these genes associated with FQ resistance and then used rapid techniques to identify those mutants. In addition, we selected spontaneous FQ-resistant mutants of Mycobacterium bovis BCG and several M. tuberculosis strains and describe here the frequency and nature of these mutations.
MATERUILS AND METHODS
Cloning of the M. tuberculosis DNA gyrase genes. A genomic library of M. tuberculosis H37Rv, constructed in the shuttle cosmid vector pYUB18, was the gift of Lisa Pascopella (15) .
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The library was screened by colony hybridization to a 0. 9-kb BglII fragment of the novobiocin-resistant Streptomyces sphaeroides gyrB gene on plasmid pLST182, which was provided by Eric Cundliffe and Amrik Thiara (26) . To confirm that the cosmids that hybridized to gyrB contained the correct region of the chromosome, they were digested with appropriate restriction enzymes and were then subjected to Southern blotting and hybridization with a series of gene-specific probes: a 1.8-kb EcoRI-BamHI fragment of the Streptomyces coelicolor dnaA gene, from plasmid pTB9018, given by Michael Calcutt (3) , a 0.7-kb PCR fragment carrying the oriC locus of Streptomyces lividans supplied by Hilde Schrempf (35) , and a fragment of Mycobacterium smegmatis gyrA amplified by using primers representing conserved regions of gyrase A (13) . Two very similar cosmids, T776 and pIV305, hybridized to all four probes and were then used as sources of DNA to generate a series of subclones in vector pUC118 or pUC119; these were then sequenced by using the Sequenase 2.0 kit with 7-deazadGTP (United States Biochemicals, Cleveland, Ohio).
In (25) . Studies of the susceptibilities of the strains to ciprofloxacin were done by radiometric methods (20 to generate a 320-bp PCR product. For sequencing, PCR products were converted to single strands by using alkaline denaturation in conjunction with streptavidin-coated magnetic beads (Dynabeads M-280; Dynal, Oslo, Norway) as outlined previously (14) . GyrA2 was used as the sequencing primer with T7 DNA polymerase (Sequenase). PCR-SSCP was performed as described previously (24) . In addition, primers were designed cessful. However, strongly hybridizing cosmids were obtained by using the gyrB probe that was recently isolated from S. sphaeroides (26) , which is phylogenetically much closer to the mycobacteria. These clones were then subjected to hybridization analysis with a set of probes for genetic loci known to be linked to gyrB in other gram-positive bacteria. Two cosmids (T776 and pIV305) with similar restriction profiles were found to hybridize with the gyrA, gyrB, oriC, and dnaA probes, whereas several others hybridized with one to three of these probes. A 5-kb BamHI fragment carried the oriC and dnaA loci, while the DNA gyrase genes appeared to be located on several BamHI fragments: 2.3 kb (gyrA), 0.9 kb (gyrBA),. and 1.5 kb and two fragments of <0.5 kb (gyrB).
As part of the M. tuberculosis genome project, an ordered collection of cosmid clones is being established by a combination of fingerprinting and hybridization analyses and the resultant contig map is being correlated with the DraI macrorestriction map of the chromosome. The DNA gyrase genes are located on a 480-kb DraI fragment in M. tuberculosis H37Rv . A 100-kb segment of the contig carrying the gyrB-dnaA region is depicted in Fig. 1 , where it can be seen that three 774 TAKIFF ET AL. other known genes are located nearby (6, 19a) . These encode the RecA recombinase (recA) and the putative thymidylate synthase (thyS) and sigma factor (hrd). Details of the construction of the map will be published elsewhere. Nucleotide sequence analysis of DNA gyrase genes. Suitable restriction fragments from cosmids pIV305 and T776 were subcloned, and their nucleotide sequences were determined. On examination of the resultant composite DNA sequence, the gyrA gene (2,517 bp) was found to be located 36 bp downstream of gyrB (2,060 bp). The deduced M. tuberculosis GyrB protein showed 79 and 63% amino acid similarities with the S. sphaeroides and E. coli proteins, respectively (Fig. 2) . The deduced GyrA protein showed 69 and 68% similarities with the E. coli and Staphylococcus aureus GyrA proteins, respectively (Fig. 3 ). The gyrase of M. tuberculosis also exhibited considerable homology with the type IV topoisomerase of E. coli ParC and ParE (16): 62% amino acid similarity between ParC and GyrB and 59% amino acid similarity between ParE and GyrA. The nucleotide sequence corresponding to the GyrA region associated with FQ resistance in M. tuberculosis is shown in Fig. 4 .
Generation of ciprofloxacin-resistant mutants. M. bovis BCG was plated onto 7H11 plates with 0.5 p,g to 3.0 mg of ciprofloxacin per ml, and spontaneously resistant colonies appeared at the frequencies given in Table 1 (Fig. 5) . The corresponding mutations (Table 2) involved four codons within the well-described region of FQ resistance (Fig.  4) (31) . One strain for which the ciprofloxacin MIC was 2 ,ug/ml presented with a genotype of ciprofloxacin susceptibility. Without exception, all laboratory strains, laboratory mutants, and ciprofloxacin-resistant clinical isolates were evaluated by PCR-SSCP and sequenced. Ciprofloxacin-susceptible clinical isolates were characterized by PCR-SSCP, sequencing, or both. Screening of the putative gyrB quinolone resistance region previously described in E. coli and other bacteria resulted in a single SSCP pattern for all evaluated strains.
DISCUSSION
Although the amino acid sequences of the DNA gyrases are well conserved in various bacteria (13) , the M. tuberculosis DNA gyrase genes could not be identified by hybridization to probes from either E. coli or B. subtilis but were easily selected with a probe for the S. sphaeroides gyrB gene. These findings can be explained by the much closer dG+dC content of Mycobacterium and Streptomyces species, and this interpretation is supported by the cross-hybridization observed between their dnaA and oriC loci. Nevertheless, the putative FQ resistance-determining region of M. tuberculosis gyrA was found to be quite similar to those from other organisms; this region is located at the highly conserved (interspecies) Nterminal protein region (31) , and the mutations encountered in ciprofloxacin-resistant M. tuberculosis clinical isolates and spontaneously arising ciprofloxacin-resistant BCG, Erdman, and H37Ra strains were located in codons equivalent to those in the gyrA genes of other ciprofloxacin-resistant bacteria (8, 19, 22, 31, 33) . Similarly, the regions of gyrB where mutations have been described in E. coli (5, 34) and which lead to resistance to coumarin compounds (coumermycin Al, novobiocin, and clorobiocin) and to the quinolone compound nalidixic acid were found to be highly conserved among M tuberculosis and other bacteria.
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We found gyrA mutations in all strains for which the ciprofloxacin MIC was >2 ,ug/ml, a level which appears to be useful in the evaluation of clinical isolates and which has been proposed as a cutoff for clinical resistance (9) . The isolated at frequencies ranging from 10-6 to 10-8. These frequencies appear to be slightly higher than those seen in the enteric bacteria (11) .
Are these the only mutations in these strains involved in their resistance to ciprofloxacin? The initial level of ciprofloxacin at which the resistant mutants were selected, 0.5 to 2.0 ,ug/ml, is only two to eight times the reported MIC range (0.25 to 1.0 ,ug/ml) for M tuberculosis (9) . Primary mutants resistant to more than 2 ,ug of ciprofloxacin per ml were not obtained in the initial selection. Difficulties in obtaining high-level resistance in a single step and the need for repeated subculturing in low concentrations of FQs for the selection of high-level FQ-resistant strains have been described for other bacteria (1, 12, 18) . In S. aureus, resistance to quinolones is achieved in two sequential steps: a first event resulting in a moderate increase in MICs and a second step in which a mutation in gyrA takes place (12) . Accumulation of additional mutations in the FQ resistance region of gyrA may lead to even higher levels of resistance (10) . Thus, in vitro data suggest that more than one step is required for the development of high-level resistance, and such multistep development of resistance may occur during therapy (21) . We did not determine the MICs for our preliminary mutants and we did not look for gyrA mutations in our preliminary mutants prior to replating of the mutants in higher concentrations of ciprofloxacin. Those mutants are no longer available for testing, and thus, we cannot rule out the possibility that, as in S. aureus, our method would first select for mutations involving drug uptake or other resistance mechanisms which result in a lower level of resistance (27, 32) and that the gyrA mutations were a subsequent event (12) . It is also possible that the M. bovis BCG and M tuberculosis mutants or clinical isolates contained other mutations in their DNA gyrase genes. However, we screened by SSCP the region where mutations that confer quinolone resistance most commonly arise in E. coli gyrB (34) However, the use of FQs in a regimen that is failing or in noncompliant patients will facilitate the emergence of resistant strains. This is illustrated by two of the clinical isolates investigated here: MDR-TB strains from New York City, which shared the same rifampin resistance rpoB mutation (23) and appeared to be clonal on the basis of fingerprint analysis (28) . However, they were found to have different gyrA mutations, which suggests that both of the patients from whom the two isolates were obtained were infected with the same MDR-TB organism and, later on, developed FQ resistance independently.
May specific mutations predict the level of resistance? In E. coli, different gyrA substitutions are associated with different ciprofloxacin MICs (33) . This could be the case in M. tuberculosis, because our preliminary assessment of clinical isolates identified some mutations which were associated with ciprofloxacin MICs of 4 to 8 ,ug/ml, and others were associated with MICs of >8 ,ug/ml. It is also conceivable that not all mutations will result in resistance to different compounds from the same family; M. tuberculosis displays discrepant susceptibility patterns to rifabutin and rifampin that are dependent on the type and location of the mutation within the rifampin resistance region of rpoB (2) . However, because resistance to FQs results from more than one mutational event, it may not be possible to establish a firm relationship between specific gyrA mutations, ciprofloxacin MICs, and variable susceptibilities to other FQs.
The knowledge of the nucleotide and amino acid sequences of the gyrases and the delineation of the antibiotic resistance regions (to quinolones and coumarin drugs) provided by the results of the present study will serve as useful bases for the assessment of the mechanisms of action and the molecular basis of resistance to new compounds of those families or other drugs which putatively target the gyrase.
